In collaboration with Childrenâs Hospital Los Angeles (CHLA) and other US academic partners, NanoValent is developing novel therapeutic options with enhanced target and delivery characteristics. The firm's experience management team has a proven track record and is supported by a strong clinical and operational support group. So far developed ahs been three HPLN (Hybrid Polymerized Liposomal Nanoparticle) based TNS (Targeted Nanosphere) candidates in oncology in close collaboration with CHLA: NV101, NV102 and NV103. These first NVP candidates (NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and NV103 (Irinotecan-anti-CD99) are approaching phase 1 and validating programs in Ewing sarcoma (with NV101 and NV103) are underway. A program in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is also envisaged with NV102. In addition NVP has developed with Boston University the highly novel NV201, a fibrin targeted, PSM (Polymerized Shell Microbubble) ultrasound activated microsphere (TMS), that shows early promise in diagnosing and treating surgical adhesions. The firm's technology offers the promise of enabling significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted HPLN loaded with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen has been even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. Already experienced has been similar - perhaps greater - potential of enhanced power and control in NV103 versus already approved benchmark products, and it has been decided to make this the firm's leading candidate. With basic clinical validation in NV103 achieved, the expectation is that NanoValent 's progression as company will alow application of the firm's IP to various challenges in adult oncology and beyond
